|
Volumn 7, Issue 6, 2001, Pages 575-579
|
Does the HEDIS asthma measure go far enough?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIASTHMATIC AGENT;
ANTIINFLAMMATORY AGENT;
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
BRONCHODILATING AGENT;
CORTICOSTEROID DERIVATIVE;
CROMOGLYCATE DISODIUM;
INFLUENZA VACCINE;
LEUKOTRIENE RECEPTOR AFFECTING AGENT;
METHYLXANTHINE DERIVATIVE;
NEDOCROMIL;
ASTHMA;
CHILD HOSPITALIZATION;
CHILDHOOD DISEASE;
CLINICAL TRIAL;
DISEASE CONTROL;
DISEASE SEVERITY;
EMERGENCY HEALTH SERVICE;
HEALTH CARE PLANNING;
HEALTH CARE QUALITY;
HIGH RISK POPULATION;
HUMAN;
NOTE;
OUTCOMES RESEARCH;
PRESCRIPTION;
PRIORITY JOURNAL;
VALIDATION PROCESS;
ANTI-ASTHMATIC AGENTS;
ASTHMA;
HEALTH BENEFIT PLANS, EMPLOYEE;
HUMANS;
OUTCOME ASSESSMENT (HEALTH CARE);
QUALITY INDICATORS, HEALTH CARE;
RISK FACTORS;
UNITED STATES;
|
EID: 0034990462
PISSN: 10880224
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
Times cited : (9)
|
References (34)
|